• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHEN Yiling, FENG Jiangjiang, YANG Haixue, SHI Yaping, LI Longnan, FENG Fang. Determination of genotoxic impurities of alkyl methanesulfonates in methanesulfonic acid by gas chromatography–mass spectrometry[J]. Journal of China Pharmaceutical University, 2020, 51(4): 472-478. DOI: 10.11665/j.issn.1000-5048.20200413
Citation: CHEN Yiling, FENG Jiangjiang, YANG Haixue, SHI Yaping, LI Longnan, FENG Fang. Determination of genotoxic impurities of alkyl methanesulfonates in methanesulfonic acid by gas chromatography–mass spectrometry[J]. Journal of China Pharmaceutical University, 2020, 51(4): 472-478. DOI: 10.11665/j.issn.1000-5048.20200413
shu

Determination of genotoxic impurities of alkyl methanesulfonates in methanesulfonic acid by gas chromatography–mass spectrometry

  • 1.

    Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 211198

  • 2.

    Wuxi Center for Drug Safety Control, Wuxi 214028

  • 3.

    Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.,Nanjing 210049,China

Funds: This study was supported by Chinese Pharmacopoeia Commission on the Research and Revision of Drug Standards (No. ZG2018-4-03)
More Information
  • Received Date: May 07, 2020
    Graphical Abstract
    • Abstract
  • An analytical liquid-liquid extraction-gas chromatography–mass spectrometry (LLE-GC-MS) method was established for the determination of genotoxic impurities including methyl methanesulfonate (MMS), ethyl methanesulfonate (EMS) and isopropyl methanesulfonate (IMS) in methanesulfonic acid. An Agilent HP-1MS capillary column (30 m × 0.32 m, 1 μm) was used for separating the analytes by programmed heating with the inlet temperature of 220 °C. Mass spectrometry was operated in positive ion mode, and selective ion monitors were set at m/z 80 for MMS, m/z 79 for EMS, m/z 123 for IMS and m/z 56 for internal standard butyl methanesulfonate (BMS). Results showed that the baseline separation of MMS, EMS and IMS was achieved, and the blank extraction solution had no interference; good linearity was achieved in the range of 37-1 480 ng/mL for three alkyl methanesulfonates; The mean recoveries of MMS, EMS, IMS were 104.99%, 107.26%,108.85%, respectively, with RSD ≤ 4.54%. The established method has the characteristics of good specific, sensitive, accurate, stable and versatility, and has been used for the detection and control of alkyl methanesulfonate impurities in methanesulfonic acid from a variety of manufacturers.
    • FullText(HTML)
    • References (18)
  • [1]
    Glowienke S, Frieauff W, Allmendinger T, et al. Structure-activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters[J]. Mutat Res-Gen Tox En, 2005,581(1/2): 23-34.
    [2]
    Clapp NK, Craig AW, Toya Sr RE. Oncogenicity by methyl methanesulfonate in male RF mice[J]. Science, 1968, 3844(161): 913-914.
    [3]
    Pfister T, Chapelon AE. General 4-week toxicity study with EMS in the rat[J]. Toxicol Lett, 2009,190(3):271-285.
    [4]
    Coffing SL, Kenyon MO, Ackerman JI, et al. Evaluation of the in vivo mutagenicity of isopropyl methanesulfonate in acute and 28‐day studies[J]. Environ Mol Mutagen, 2015, 56(3):322-332.
    [5]
    European Medicines Agency. The following letter is intended for all marketing authorization holders for medicinal products containing active substances in the form of mesilates, (di) isetionates, tosilates or besilates (EMEA/44714/2008) [S]. London: European Medicines Agency, 2008.
    [6]
    Center for Drug Evaluation and Research. Guidance for industry: genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft) [S]. Rockvill: U.S. Food and Drug Administration, 2008.
    [7]
    National Medical Products Administration. Technical guidance on genotoxicity testing (药物遗传毒性研究技术指导原则) [EB/OL]. (2018-03-12) [2020-05-07]. http://www.nmpa.gov.cn/WS04/CL2138/300523.html.
    [8]
    Chinese Pharmacopoeia Commision. Chinese Pharmacopoeia: Part 4 (中华人民共和国药典:四部)[S]. Beijing: China Medical Science Press, 2020: 527-530.
    [9]
    Teasdale A, Eyley SC, Delaney ED, et al. Mechanism and processing parameters affecting the formation of methyl methanesulfonate from methanol and methanesulfonic acid: an illustrative example for sulfonate ester impurity formation[J]. Org Process Res Dev, 2009,13(3):429-433.
    [10]
    Teasdale A, Delaney EJ, Eyley SC, et al. A detailed study of sulfonate ester formation and solvolysis reaction rates and application toward establishing sulfonate ester control in pharmaceutical manufacturing processes[J]. Org Process Res Dev, 2010, 14(4):999-1007.
    [11]
    Shen DD, Zhu JL, Wu GF, et al. Development of synthesis of phosphatidylinositol 3-kinases inhibitor puquitinib mesylate [J]. Chin J Org Chem（有机化学）, 2019, 39(9):2676-2680.
    [12]
    Elder D, Facchine KL, Levy JN, et al. An approach to control strategies for sulfonate ester formation in pharmaceutical manufacturing based on recent scientific understanding[J]. Org Process Res Dev, 2012, 16(11):1707-1710.
    [13]
    Ramjitt HG, Singh MM, Coddington AB, et al. Gas chromatographic/mass spectrometric analysis of methyl methanesulphonate and ethyl methanesulphonate in the bismesylate salt of DPI 201-106, a positive inotropic agent for the treatment of heart failure[J]. J Mass Spectrom, 1996, 31(8): 867-872.
    [14]
    Zhou J, Xu J, Zheng XY, et al. Determination of methyl methanesulfonate and ethyl methanesulfonate in methanesulfonic acid by derivatization followed by high-performance liquid chromatography with ultraviolet detection[J]. J Sep Sci ,2017,40(17):3414-3421.
    [15]
    European Directorate for Quality and Medicines＆HealthCare (EDQM). European Pharmacopoeia Supplement 7.1 [S]. Strasbourg: Council of Europe, 2011:3321.
    [16]
    Zhang CZ, Huang L, Wu ZG, et al. Determination of sulfonate ester genotoxic impurities in imatinib mesylate by gas chromatography with mass spectrometry [J]. J Sep Sci, 2016, 39(18):3558-3563.
    [17]
    Wollein U, Schramek N. Simultaneous determination of alkyl mesilates and alkyl besilates in finished drug products by direct injection GC/MS[J]. Eur J Pharm Sci, 2012, 45(1/2):201-204.
    [18]
    Qian C, Gou XL, Hu GH, et al. Determination of residual mesylate esters in lurasidone hydrochloride tablets by GC-MS/SIM[J]. Anal Instru（分析仪器）,2018(01):199-203.
    • Related Articles

  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [3]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [4]YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
    [5]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [6]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [9]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.

  • Cited by

    Periodical cited type(0)

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (282) PDF downloads (537) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：286205

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return